Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Peripheral Nervous System Diseases 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Colorectal Neoplasms 2Wilms Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Oral Complications 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Dexamethasone 338Bortezomib 188Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × Glutamine × Clear all
NCT01783522 2019-10-22

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Case Comprehensive Cancer Center

Phase 2 Terminated
9 enrolled 10 charts
Plasma cell

Multiple Myeloma, Peripheral Nervous System Diseases

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡